Tg Therapeutics (TGTX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$799.5M

Revenue (quarter)

$240.3M

Revenue growth (year over year)

+70.27%

Gross profit (trailing twelve months)

$658.6M

Gross margin

82.37%

Net income (trailing twelve months)

$441.5M

Net income (quarter)

$7.8M

Net income growth (year over year)

−72.40%

Net margin

55.22%

Return on equity

100.28%

EPS (trailing twelve months)

$3.06

Book value per share

$3.95

P/E (trailing twelve months)

19.42

Price to book

14.19

Debt to assets

63.16%

Payout ratio

—

Dividend yield

—

Company profile

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

• Is Tg Therapeutics (TGTX) profitable?

  Yes. Tg Therapeutics earned $441.5M in net income over the trailing twelve months, a net margin of 55.22%.

• How much revenue does Tg Therapeutics (TGTX) make?

  Tg Therapeutics generated $799.5M in revenue over the trailing twelve months, up 70.27% year over year.

• What is TGTX's P/E ratio?

  Tg Therapeutics trades at 19.4 times trailing twelve-month earnings, on an EPS of $3.06.

• How do I buy stock in Tg Therapeutics (TGTX)?

  TGTX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.